Approximately 20% of BCs harbor ERBB2/Her2 gene amplification [25,26], while FGFR1 and FGFR2 amplification are reported in around 14% and 4% of patients with BC, respectively [27,28]. This evidence concerns the gene ERBB2 and breast cancer.